Browsing: rare

Mirage News Mirage News Mirage NewsScience23 Jul 2026 3:14 am AESTDate Time King’s College London

The 16-year-old son of Kourtney Kardashian Barker and Scott Disick shared a rare Instagram story of a car that every teen wishes for. Mason posted a photo of a dark green Vintage Ford Bronco to his 765k Instagram followers proving just how lucky he is

While the U.S. continues to be the world leader in developing treatments for rare diseases, other countries—China especially—are catching up and could ultimately cause Americans to miss out on crucial medicines, a group of Congressional advisors argues

Eton Pharmaceuticals (ETON) drew fresh attention after its stock climbed 13.8% on strong trading volume, with interest centering on its commercial rare disease portfolio and late-stage candidates such as Amglidia and the Zeneo hydrocortisone autoinjector

&nbsp Featured|Markets|Science and Technology Author: Massimo Radaelli, President & CEO, Napo Therapeutics

It’s estimated that nearly 400 million people across the globe live with a rare disease. Though many of these diseases are progressive, debilitating, and even life-threatening, less than five percent of them have an effective and approved treatment

Neustrashimy suddenly announced it intended to fire its guns and conducted 30-minute drill south of Plymouth

Last spring, we announced Anthropic’s AI for Science program, an initiative designed to accelerate scientific research and discovery through access to our API. Since launching, we have supported researchers working on a variety of high-impact projects, ranging from drug repurposing to quantum simulation. Throughout this initiative, we have found that projects are more generative when…

“Obtaining regulatory approval is one part of the challenge for rare disease therapies. Following approval, HTA agencies and payers evaluate the clinical, economic, and patient-centered value of a therapy to inform pricing, reimbursement, and patient access decisions. Historically, rare disease trials have often relied on small patient populations, single-arm or open-label designs, surrogate endpoints, and…

Ultragenyx Pharmaceutical (RARE) stock continues to trade with recent moves shaped largely by its rare disease portfolio and late stage pipeline. This has prompted investors to reassess risk, growth potential, and current valuation